---
schema_version: "secwatch.filing_event.v1"
accession: "0001964738-25-000013"
form_type: "8-K"
ticker: "SOLV"
cik: "0001964738"
company_name: "Solventum Corp"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:35:07.688229+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Solventum Q4 2024: GAAP EPS $0.17, adj. EPS $1.41, organic sales +2.3%

## Summary
- GAAP diluted EPS $0.17; adjusted EPS $1.41; sales $2,074M (+1.9% reported, +2.3% organic).
- GAAP operating income $136M (6.6% margin); adjusted $422M (20.4% margin); MedSurg and Dental drove growth.
- Generated $219M cash from operations; free cash flow $92M.
- Full-year 2024: sales $8,254M, GAAP EPS $2.76, adjusted EPS $6.70, free cash flow $805M.
- Introduced FY 2025 guidance for organic sales growth, adjusted EPS, and free cash flow (specific figures not provided).

## SEC filing metadata
- accession: 0001964738-25-000013
- form_type: 8-K
- ticker: SOLV
- cik: 0001964738
- company_name: Solventum Corp
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964738/000196473825000013/0001964738-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964738/000196473825000013/solv-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001964738-25-000013
- JSON: https://secwatch.observer/filing/0001964738-25-000013.json
- Plain text: https://secwatch.observer/filing/0001964738-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.